| Protein | Protein Name | Molecular Type | Hallmark | Feature | Evidence | Reference |
|---|
| TGFBR2 | Transforming growth factor, beta receptor II | Receptor Serine/threonine Kinase | Tumour Microenvironment | Cancer Microenvironment | TbetaRII expression occurred in the stromal compartments of human primary prostate cancer and prostate cancer bone metastatic tissues | Reference |
| TGFBR2 | Transforming growth factor, beta receptor II | Receptor Serine/threonine Kinase | Insensitivity to Anti-Growth Signal | Tumor Suppression | It functions as a tumor suppressor in early tumorigenesis; it follows loss of expression, epigenetic silencing, mutation and down regulation during prostate tumorigenesis. | Reference |
| TGFBR2 | Transforming growth factor, beta receptor II | Receptor Serine/threonine Kinase | Insensitivity to Anti-Growth Signal | Tumor Suppression | Overexpression of TGFBR2 LNCaP prostate cancer cells induces prostate tumorigenic suppression by caspase dependent apoptosis | Reference |
| TGFBR2 | Transforming growth factor, beta receptor II | Receptor Serine/threonine Kinase | Insensitivity to Anti-Growth Signal | Tumor Suppression | Although TGF-beta inhibits the proliferation of normal prostate cells and functions as a tumor suppressor in early tumorigenesis, it acts as a tumor promoter in later stages of tumor progression | Reference |
| TGFBR2 | Transforming growth factor, beta receptor II | Receptor Serine/threonine Kinase | Self-Sufficiency in Growth Signal | Cell Proliferation | During endothelial & perineural invasion TGF beta mediated enhanced secretion of CAV1 into the tumor microenvironment causes marked increase of proliferative activity in prostate cancer cell | Reference |
| TGFBR2 | Transforming growth factor, beta receptor II | Receptor Serine/threonine Kinase | Genome Instability, Mutation & Perturbation | Loss of Expression | Frequent loss of TGFBR2 expression | Reference |
| TGFBR2 | Transforming growth factor, beta receptor II | Receptor Serine/threonine Kinase | Genome Instability, Mutation & Perturbation | Loss of Expression | Frequent loss of TGFBR2 expression is assocoated with the development of human prostate cancer. | Reference |
| TGFBR2 | Transforming growth factor, beta receptor II | Receptor Serine/threonine Kinase | Genome Instability, Mutation & Perturbation | | Downregulation of TGFBR2 in human prostate cancer. | Reference |
| TGFBR2 | Transforming growth factor, beta receptor II | Receptor Serine/threonine Kinase | Angiogenesis | Angiogenesis | Over-expression of TGF-beta aids tumorigenesis by not only stimulating angiogenesis and suppressing the immune system, but also by acting directly on the prostate tumor cells | Reference |
| TGFBR2 | Transforming growth factor, beta receptor II | Receptor Serine/threonine Kinase | Metastasis | Metastasis | disruption of TGF-beta signaling in prostate cancer plays a causal role in promoting tumor metastasis | Reference |
| TGFBR2 | Transforming growth factor, beta receptor II | Receptor Serine/threonine Kinase | Metastasis | Metastasis | disruption of TGF-beta signaling in prostate cancer plays a causal role in promoting tumor metastasis | Reference |
| TGFBR2 | Transforming growth factor, beta receptor II | Receptor Serine/threonine Kinase | Metastasis | Cell Invasion | During endothelial & perineural invasion TGF beta mediated enhanced secretion of CAV1 into the tumor microenvironment causes marked inhibition of prostate cancer apoptosis | Reference |
| TGFBR2 | Transforming growth factor, beta receptor II | Receptor Serine/threonine Kinase | Metastasis | Cell Motility | TGFBR2 promotes cell motility | Reference |
| TGFBR2 | Transforming growth factor, beta receptor II | Receptor Serine/threonine Kinase | Metastasis | Epithelial Mesenchymal Transition(EMT) | Increased production of TGF beta causes epithelial mesenchymal transition | Reference |
| TGFBR2 | Transforming growth factor, beta receptor II | Receptor Serine/threonine Kinase | Metastasis | Epithelial Mesenchymal Transition(EMT) | Increased production of TGF beta causes epithelial mesenchymal transition | Reference |
| TGFBR2 | Transforming growth factor, beta receptor II | Receptor Serine/threonine Kinase | Metastasis | Cell Adhesion | Loss of TGFBR2 responsiveness is involved in prostate cancer cell adhesion in bone matrix. | Reference |
| TGFBR2 | Transforming growth factor, beta receptor II | Receptor Serine/threonine Kinase | Cell Death Resistance | Aoptosis Resistance | During endothelial & perineural Cell Invasion TGF beta mediated enhanced secretion of CAV1 into the tumor microenvironment causes marked inhibition of prostate cancer apoptosis | Reference |
| TGFBR2 | Transforming growth factor, beta receptor II | Receptor Serine/threonine Kinase | Cell Death Resistance | Aoptosis Resistance | Overexpression of BCL2 leads to androgen independent prostate cancer by resistance of TGF beta mediated apoptosis | Reference |
| TGFBR2 | Transforming growth factor, beta receptor II | Receptor Serine/threonine Kinase | Enabling Replicative Immortality | Telomere maintenance | Supress telomerase expression | Reference |
| TGFBR2 | Transforming growth factor, beta receptor II | Receptor Serine/threonine Kinase | Avoidance of Immune Destruction | Immune Evasion | Over-expression of TGF-beta aids tumorigenesis by not only stimulating angiogenesis and suppressing the immune system, but also by acting directly on the prostate tumor cells | Reference |